Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022

Vaccine developer Novavax Inc said on Friday at least 2 billion doses of its COVID-19 vaccine would be available in 2022. The company, which in June announced its vaccine was more than 90% effective in a late-stage U.S.-based clinical trial, said it was on track to file an application for emergency use of its vaccine to the U.S. Food and Drug Administration in the fourth quarter. Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it would have about 100 million doses per month by the end of the third quarter this year, and would increase it to 150 million doses in the fourth quarter.

Novavax expects to make available at least 2 billion COVID-19 vaccine doses in 2022 Read More »

20 years later, legal case against accused 9/11 mastermind grinds on

Hours before the 20th anniversary of the 9/11 terrorist attacks, pretrial proceedings in the case against the five accused orchestrators started and ended on Friday with none of them present in the courtroom for the final public session of the week – while multiple defense teams raised formal objections against the judge continuing to preside over the military commission. Khalid Sheikh Mohammed, the self-proclaimed mastermind of the attacks, had been present during public sessions of the proceedings on Tuesday and Wednesday this week, even taking the rare moment out of his detention cell to wave at reporters in the public gallery in the courtroom. An assistant staff judge advocate, identified only by a pseudonym “Pa,” testified to their absence and provided signatures acknowledging their “voluntary” decision not to attend.

20 years later, legal case against accused 9/11 mastermind grinds on Read More »

Advantex Announces Second Tranche of Debenture Financing

Advantex Marketing International Inc. (CSE: ADX) (“Advantex”), a leader in the merchant cash advance and loyalty marketing products for merchants, is pleased to announce that it has closed the second tranche of its senior secured non-convertible debentures for gross proceeds of $1,000,000 (the “Financing”). The Financing was approved by Advantex shareholders at Advantex’s special meeting of shareholders on August 26, 2021 (the “Meeting”).

Advantex Announces Second Tranche of Debenture Financing Read More »

Shopping Cart